Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;64(3):372-388.
doi: 10.1007/s11427-020-1714-8. Epub 2020 Aug 11.

Triple-negative breast cancer: new treatment strategies in the era of precision medicine

Song-Yang Wu #  1 , Hai Wang #  1 , Zhi-Ming Shao  1 , Yi-Zhou Jiang  2
Affiliations
Review

Triple-negative breast cancer: new treatment strategies in the era of precision medicine

Song-Yang Wu et al. Sci China Life Sci. 2021 Mar.

Abstract

Triple-negative breast cancer (TNBC) remains the most aggressive cluster of all breast cancers, which is due to its rapid progression, high probabilities of early recurrence, and distant metastasis resistant to standard treatment. Following the advances in cancer genomics and transcriptomics that can illustrate the comprehensive profiling of this heterogeneous disease, it is now possible to identify different subclasses of TNBC according to both intrinsic signals and extrinsic microenvironment, which have a huge influence on predicting response to established therapies and picking up novel therapeutic targets for each cluster. In this review, we summarize basic characteristics and critical subtyping systems of TNBC, and particularly discuss newly found prospective targets and relevant medications, which were proved promising in clinical trials, thus shedding light on the future development of precision treatment strategies.

Keywords: molecular subtype; precision medicine; targeted therapy; triple-negative breast cancer.

PubMed Disclaimer

References

    1. Adams, S., Diamond, J.R., Hamilton, E., Pohlmann, P.R., Tolaney, S.M., Chang, C.W., Zhang, W., Iizuka, K., Foster, P.G., Molinero, L., et al. (2019a). Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up. JAMA Oncol 5, 334–342. - PubMed
    1. Adams, S., Gatti-Mays, M.E., Kalinsky, K., Korde, L.A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H.L., Frank, E., Perlmutter, J., et al. (2019b). Current landscape of immunotherapy in breast cancer. JAMA Oncol 5, 1205.
    1. Adams, S., Loi, S., Toppmeyer, D., Cescon, D.W., De Laurentiis, M., Nanda, R., Winer, E.P., Mukai, H., Tamura, K., Armstrong, A., et al. (2019c). Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol 30, 405–411. - PubMed
    1. Adams, S., Schmid, P., Rugo, H.S., Winer, E.P., Loirat, D., Awada, A., Cescon, D.W., Iwata, H., Campone, M., Nanda, R., et al. (2019d). Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30, 397–404. - PubMed
    1. Afghahi, A., Purington, N., Han, S.S., Desai, M., Pierson, E., Mathur, M.B., Seto, T., Thompson, C.A., Rigdon, J., Telli, M.L., et al. (2018). Higher absolute lymphocyte counts predict lower mortality from early-stage triple-negative breast cancer. Clin Cancer Res 24, 2851–2858. - PubMed - PMC

MeSH terms

LinkOut - more resources